Pharmacologic therapy of chronic heart failure

American Journal of Cardiovascular Drugs

Volumn 7, Issue 4, 2007, Pages 235-248

  Hamad, Eman ^a   Mather, Paul J ^a   Srinivasan, Siva ^a   Rubin, Sharon ^a   Whellan, David J ^a   Feldman, Arthur M ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM SENSITIZER; CANDESARTAN; CAPTOPRIL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; ENALAPRIL; ENALAPRIL MALEATE; EPLERENONE; FOSINOPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; METOPROLOL; MILRINONE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; QUINAPRIL; RAMIPRIL; SPIRONOLACTONE; UNINDEXED DRUG; VALSARTAN;

BLOOD PRESSURE; BLOOD VESSEL TONE; BLOOD VOLUME; CONGESTIVE CARDIOMYOPATHY; CONTINUOUS INFUSION; DIASTOLE; DRUG EFFICACY; DRUG TOLERABILITY; FLUID BALANCE; HEART FAILURE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HEMODYNAMICS; HUMAN; KIDNEY FUNCTION; LOADING DRUG DOSE; LOW DRUG DOSE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTOLE; TREATMENT DURATION; TREATMENT OUTCOME; VASOCONSTRICTION;

ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOTONIC AGENTS; CHRONIC DISEASE; DIGOXIN; DIURETICS; HEART FAILURE, CONGESTIVE; HUMANS; RECEPTORS, ALDOSTERONE; RECEPTORS, ANGIOTENSIN; VASODILATOR AGENTS;

EID: 34548143017     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200707040-00002     Document Type: Review

References (77)

1. American Heart Association. Heart disease and stroke statistics: 2004 update. Dallas (TX): American Heart Association, 2004
2. Levy D, Kenchaiah S, Larson MF, et al. Long term trends in the incidence of and survival with heart failure. N Eng J Med 2002; 347: 1397-402
3. Owan T, Hodge D, Herges R, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Eng J Med 2006; 355: 251-9
4. Waagstein F. Beneficial effects of metoprolol in diopathic dilated cardiomyopathy. Metroprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1993; 342: 1441-9
5. Colucci WS, Packer M, Bristow MR, et al. US carvedilol heart failure study. Circulation 1996; 94 (11): 2800-6
6. CIBIS II Scientific Committee. Design of the Cardiac Insufficiency Bisoprolol Study II (CIBIS II). Fundam Clin Pharmacol 1997; 11: 138-42
7. MERIT-HF Study Group. Effect of metoprolol CR/XL on chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-9
8. Packer M, Coats AJ, Fowler MB. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-8
9. Willenheimer R, Erdmann E, Follath F. Comparison of treatment initiation with bisoprolol vs enalapril in chronic heart failure patients: rationale and design of CIBIS III. Eur J Heart Fail 2004; 6: 493-500
10. Lowes BD, Gilbert EM, Abraham WT, et al. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med 2002; 346: 1357-65
11. Ventura-Clapier R, Garnier A, Veksler V. Energy metabolism in heart failure. J Physiol 2003; 555: 1-13
12. 2-Adrenergic receptor pharmacogenetics. Am J Respir Crit Care Med 2000; 161: 197-201
13. CIBIS investigators and committees. A randomized trial of β-blockade in heart failure: the cardiac insufficiency bisoprolol study (CIBIS). Circulation 1994; 90: 1765-73
14. The Australia-New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997; 349: 375-80
15. The BEST Steering Committee. Design of the Beta-blocker Evaluation Survival Trial. Am J Cardiol 1995; 75: 1220-3
16. Poole-Wilson PA, Sedberg K, Cleland JGF, et al. Comparison of Carvedilol and Metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomized controlled trial. Lancet 2003; 362: 7-13
17. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult-Summary Article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Circulation 2005; 112: 1825-52
18. Lee AF, MacFadyen RJ, Struthers AD. Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study. Eur J Heart Fail 1999; 1 (4): 401-6
19. Brunton L, Lazo J, Parker K, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 11th ed. (ISBN 0071422803). Columbus (OH): McGaw-Hill Professional, 2005
20. Captopril Multicenter Research Group. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol 1983; 2: 755-63
21. Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA 1988; 259: 539-44
22. CONSENSUS Trial Study Group. Effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1987; 316: 1429-35
23. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302
24. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-91
25. Pfeffer MA, Braunwald E, Moye LA. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327: 669-7
26. Kober L, Torp-Pedersen C, Carlesen JE. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study group. N Engl J Med 1995; 333: 1670-6
27. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-53
28. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-8
29. Schwartz JS, Wang YR, Cleland JGF, et al., for the ATLAS Study Group. High-versus low-dose angiotensin converting enzyme inhibitor therapy in the treatment of heart failure: an economic analysis of the assessment of treatment with lisinopril and survival (ATLAS) Trial. Am J Manag Care 2003; 9: 417-24
30. Dries DL, Strong MH, Cooper RS, et al. Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in Black and White patients. J Am Coll Cardiol 2002; 40: 311-7
31. Packer M. Adaptive and maladaptive actions of angiotensin II in patients with severe congestive heart failure. Am J Kidney Dis 1987; 10: 60-73
32. Maggioni AP, Anand I, Gottlieb SO, et al. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2002; 40: 1414-21
33. Granger CB, McMurray JJ, Yusuf S, et al., for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting- enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772-6
34. McMurray JJ, Ostergren J, Swedberg K. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767-71
35. Yusuf S, Pfeffer MA, Swedberg K, et al., for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777-81
36. Pitt B, Poole-Wilson PA, Segal R, et al., on behalf of the ELITE II investigators. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial -the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-7
37. Cohn JN, Tognoni G, on behalf of the the Valsartan Heart Failure Trial Investigators. Randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-75
38. Velazquez EJ, Pfeffer MA, McMurray JV, et al. VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context. Eur J Heart Fail 2003; 5 (4): 537-44
39. Swedberg K, Eneroth P, Kjekshus J, et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990; 82: 1730-6
40. Bozkurt B. Aldosterone antagonism in the pharmacologic management of chronic heart failure. In: Feldman AM, editor. Heart failure; pharmacologic management. Boston (MA): Blackwell, 2006
41. Pitt B, Zannad F, Remme WJ. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-17
42. de Gasparo M, Joss U, Ramjoue HP, et al. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 1987; 240: 650-6
43. Pitt B, Remme WJ, Zannad F. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-21
44. Sharon A, Hunt DW, Baker MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary (a Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure)). Circulation 2001; 104: 2996-3007
45. Antman EM, Anbe DT, Kushben FG, et al. Management of patients with STEMI: executive summary ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction -executive summary (a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction)). J Am Coll Cardiol 2004; 44: 671-719
46. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 2004; 351: 543-51
47. Felker GM, Benza RL, Chandler AB, et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 2003; 41: 997-1003
48. Thackray S, Easthaugh J, Freemantle N, et al. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure: a meta-regression analysis. Eur J Heart Fail 2002; 4: 515-29
49. Fonarow GC, Yancy CW, Heywood JT, for the ADHERE Scientific Advisory Committee, Study Group, and Investigators. Adherence to heart failure quality-of-care indicators in US hospitals: analysis of the ADHERE registry. Arch Intern Med 2005; 165: 1469-77
50. Cuffe MS, Calrif RM, Adams Jr KF. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002; 287: 1541-7
51. Seino Y, Momomura S, Takano T, et al, for the Katoh and Japan Intravenous Milrinone Investigators. Multicenter, double-blind study of intravenous milrinone for patients with acute heart failure in Japan. Crit Care Med 1996; 24: 1490-7
52. Anderson JL. Hemodynamic and clinical benefits with intravenous milrinone in severe chronic heart failure results of a multicenter study in the United States. Am Heart J 1991; 121: 1956-64
53. Packer M, Carver JR, Rodeheffer RJ, et al., the PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991; 325: 1468-75
54. Anderson JL, Baim DS, Fein SA, et al. Efficacy and safety of sustained (48 hour) intravenous infusions of milrinone in patients with severe congestive heart failure: a multicenter study. J Am Coll Cardiol 1987; 9: 711-22
55. Metra M, Nodari S, D'Aloia A, et al. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol 2002; 40: 1248-58
56. Oliva F, Latini R, Politi A, et al. Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial. Am Heart J 1999; 138: 247-53
57. Elis T, Benal O, Kimchi M, et al. Intermittent dobutamine treatment in patients with chronic refractory congestive heart failure: a randomized, double-blind, placebo-controlled study. Clin Pharmacol Ther 1998; 63 (6): 682-5
58. Adamopoulos S, Piepoli M, Qiang F, et al. Effects of pulsed beta-stimulant therapy on beta-adrenoceptors and chronotropic responsiveness in chronic heart failure. Lancet 1995; 345: 344-9
59. Erlemeier HH, Kupper W, Bleifeld W. Intermittent infusion of dobutamine in the therapy of severe congestive heart failure: long-term effects and lack of tolerance. Cardiovasc Drugs Ther 1992; 6 (4): 391-8
60. Dies F, Krell MJ, Whitlow P. Intermittent dobutamine in ambulatory outpatients with chronic cardiac failure. Circulation 1986; 74 Suppl. II: 11-38
61. Leier CV, Heban PT, Huss P. Comparative systemic and regional hemodynamic effects of dopamine and dobutamine in patients with cardiomyopathic heart failure. Circulation 1981; 63: 1279-85
62. Kass DA, Solaro RJ. Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation 2006; 113: 305-15
63. Katz SD, Kubo SH, Jessup M, et al. A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure. Am Heart J 1992; 123: 95-103
64. Kubo SH, Gollub S, Bourge R, et al. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure: results of a multicenter trial. Circulation 1992; 85: 942-9
65. Slawsky MT, Colucci WS, Gottleib SS, et al., on behalf of the Study Investigators. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 2000; 102: 2222-7
66. Nieminen MS, Akkila J, Hasenfuss G, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000; 36: 1903-12
67. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002; 360: 196-202
68. De Luca L, Colucci WS, Nieminen MS, et al. Evidence-based use of levosimendan in different clinical settings. Eur Heart J 2006; 27: 1908-20
69. Young JB, Gheorghiade M, Uretsky BF, et al. Superiority of 'triple' drug therapy in heart failure: insights from the PROVED and RADIANCE trials - prospective randomized study of ventricular function and efficacy of digoxin, randomized assessment of digoxin and inhibitors of angiotensin-converting enzyme. J Am Coll Cardiol 1998; 32: 686-92
70. Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors: RADIANCE Study. N Engl J Med. 1993; 329: 1-7
71. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525-33
72. Uretsky BF, Young JB, Shahidi FE, et al. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol 1993; 22: 955-62
73. Ward RE, Gheorghiade M, Young JB, et al. Economic outcomes of withdrawal of digoxin therapy in adult patients with stable congestive heart failure. J Am Coll Cardiol 1995; 26: 93-101
74. Gheorghiade M, Cody RJ, Francis GS, et al. Current medical therapy for advanced heart failure. Am Heart J 1998 Jun; 135 (6 Pt 2 Suppl.): S231-48
75. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 314: 1547-52
76. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure Vasodilator-Heart Failure Trial II. N Engl J Med 1991; 325: 303-10
77. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004; 351: 2049-53